Jared is a freelance writer for The American Journal of Managed Care® (AJMC®), and previously worked as a senior editor for HCPLive® at MJH Life Sciences®.
He has an MA from University of Sioux Falls. You can connect with Jared on LinkedIn.
Retrospective Analysis Suggests Allo-HSCT Feasible for R/R DLBCL After CAR T Failure
Among the 10 patients in the retrospective analysis, the median overall survival after allogeneic hematopoietic stem cell transplantation (allo-HSCT) for relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) was 21 months.
ELN Risk Category, MRD Status Predictive of Relapse in Patients With AML
The study may help explain why some patients are more prone to relapse following a complete response to induction therapy, as indicated by measurable residual disease (MRD) status and 2017 European LeukemiaNet (ELN) criteria.
Study Validates First Disease-Specific PRO Instrument for Patients With Congenital TTP
Congenital thrombotic thrombocytopenic purpura (TTP), an ultra-rare disease, can significantly impact quality of life, but clinicians have previously lacked a disease-specific way to track experiences via patient-reported outcomes (PROs).